ENTX logo

Entera Bio (ENTX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

28 June 2018

Indexes:

Not included

Description:

Entera Bio (ENTX) is a biotechnology company focused on developing oral drug delivery systems for proteins and peptides. Their innovative technology aims to improve the effectiveness of treatments for various diseases, making medications easier to take and enhancing patient compliance.

Events Calendar

Earnings

Next earnings date:

Mar 07, 2025

Recent quarterly earnings:

Nov 08, 2024

Recent annual earnings:

Mar 08, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

11 Nov '24 HC Wainwright & Co.
Buy
07 Oct '24 HC Wainwright & Co.
Buy
27 Sept '24 HC Wainwright & Co.
Buy
12 Aug '24 HC Wainwright & Co.
Buy
05 June '24 HC Wainwright & Co.
Buy
14 May '24 HC Wainwright & Co.
Buy
13 May '24 HC Wainwright & Co.
Buy
02 Apr '24 HC Wainwright & Co.
Buy
11 Dec '23 HC Wainwright & Co.
Buy
13 Sept '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
ENTX
zacks.com08 November 2024

Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
ENTX
globenewswire.com08 November 2024

JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024.

ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
ENTX
zacks.com26 September 2024

Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.

Entera Bio to Participate in Upcoming Investor and Scientific Conferences
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
ENTX
globenewswire.com20 August 2024

JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences:

All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
ENTX
zacks.com15 August 2024

Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
ENTX
globenewswire.com09 August 2024

JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.

Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade
ENTX
Zacks Investment Research26 April 2024

Entera Bio Ltd. (ENTX) closed at $1.98 on the most recent trading day, reflecting a 1% decrease from the previous closing price.

Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
ENTX
Zacks Investment Research18 April 2024

At the end of the most recent trading day, Entera Bio Ltd. (ENTX) closed at $2.24, reflecting a 0.9% increase from the previous day's closing price.

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
ENTX
Zacks Investment Research12 April 2024

Here is the performance comparison of Entera Bio Ltd. (ENTX) and FibroGen (FGEN) relative to their sector year to date.

Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
Here's Why You Should Invest in Entera Bio (ENTX) Stock Now
ENTX
Zacks Investment Research09 April 2024

In this article, we explore why purchasing Entera Bio (ENTX) stock at this time could be a wise decision.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Entera Bio?
  • What is the ticker symbol for Entera Bio?
  • Does Entera Bio pay dividends?
  • What sector is Entera Bio in?
  • What industry is Entera Bio in?
  • What country is Entera Bio based in?
  • When did Entera Bio go public?
  • Is Entera Bio in the S&P 500?
  • Is Entera Bio in the NASDAQ 100?
  • Is Entera Bio in the Dow Jones?
  • When was Entera Bio's last earnings report?
  • When does Entera Bio report earnings?
  • Should I buy Entera Bio stock now?

What is the primary business of Entera Bio?

Entera Bio (ENTX) is a biotechnology company focused on developing oral drug delivery systems for proteins and peptides. Their innovative technology aims to improve the effectiveness of treatments for various diseases, making medications easier to take and enhancing patient compliance.

What is the ticker symbol for Entera Bio?

The ticker symbol for Entera Bio is NASDAQ:ENTX

Does Entera Bio pay dividends?

No, Entera Bio does not pay dividends

What sector is Entera Bio in?

Entera Bio is in the Healthcare sector

What industry is Entera Bio in?

Entera Bio is in the Biotechnology industry

What country is Entera Bio based in?

Entera Bio is headquartered in Israel

When did Entera Bio go public?

Entera Bio's initial public offering (IPO) was on 28 June 2018

Is Entera Bio in the S&P 500?

No, Entera Bio is not included in the S&P 500 index

Is Entera Bio in the NASDAQ 100?

No, Entera Bio is not included in the NASDAQ 100 index

Is Entera Bio in the Dow Jones?

No, Entera Bio is not included in the Dow Jones index

When was Entera Bio's last earnings report?

Entera Bio's most recent earnings report was on 8 November 2024

When does Entera Bio report earnings?

The next expected earnings date for Entera Bio is 7 March 2025

Should I buy Entera Bio stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions